227 related articles for article (PubMed ID: 8762100)
1. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Berry CN; Girard D; Lochot S; Lecoffre C
Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris.
Gold HK; Torres FW; Garabedian HD; Werner W; Jang IK; Khan A; Hagstrom JN; Yasuda T; Leinbach RC; Newell JB
J Am Coll Cardiol; 1993 Apr; 21(5):1039-47. PubMed ID: 8459055
[TBL] [Abstract][Full Text] [Related]
4. Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Berry CN; Girard D; Girardot C; Lochot S; Lunven C; Visconte C
Semin Thromb Hemost; 1996; 22(3):233-41. PubMed ID: 8836007
[TBL] [Abstract][Full Text] [Related]
5. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.
Eidt JF; Allison P; Noble S; Ashton J; Golino P; McNatt J; Buja LM; Willerson JT
J Clin Invest; 1989 Jul; 84(1):18-27. PubMed ID: 2661588
[TBL] [Abstract][Full Text] [Related]
6. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
[TBL] [Abstract][Full Text] [Related]
7. Combined administration of aspirin and a specific thrombin inhibitor in man.
Clarke RJ; Mayo G; FitzGerald GA; Fitzgerald DJ
Circulation; 1991 May; 83(5):1510-8. PubMed ID: 2022012
[TBL] [Abstract][Full Text] [Related]
8. [Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis].
Ragni M; Golino P; Cirillo P; Pascucci I; Scognamiglio A; Ravera A; Esposito N; Battaglia C; Guarino A; Chiariello M
Cardiologia; 1996 Jan; 41(1):51-8. PubMed ID: 8697470
[TBL] [Abstract][Full Text] [Related]
9. [Experimental and clinical results with the thrombin inhibitor Argatroban].
Breddin HK
Hamostaseologie; 2002 Aug; 22(3):55-9. PubMed ID: 12215762
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of antithrombotic effect of heparin and antithrombin in balloon-injured arteries.
Tomaru T; Kawano HA; Tsujiuchi Y; Suzuki J; Nakajima T; Uchida Y
Life Sci; 2005 Oct; 77(21):2611-25. PubMed ID: 16005470
[TBL] [Abstract][Full Text] [Related]
11. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.
Jang IK; Gold HK; Ziskind AA; Leinbach RC; Fallon JT; Collen D
Circulation; 1990 Jan; 81(1):219-25. PubMed ID: 2297828
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model.
Imura Y; Stassen JM; Vreys I; Lesaffre E; Gold HK; Collen D
Thromb Haemost; 1992 Sep; 68(3):336-40. PubMed ID: 1440501
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Schumacher WA; Heran CL; Steinbacher TE
J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
[TBL] [Abstract][Full Text] [Related]
14. Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Guy S; Kitchen S; Maclean R; Van Veen JJ
Int J Lab Hematol; 2015 Dec; 37(6):834-43. PubMed ID: 26305560
[TBL] [Abstract][Full Text] [Related]
15. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship of coagulation parameters.
Akimoto K; Klinkhardt U; Zeiher A; Niethammer M; Harder S
J Clin Pharmacol; 2011 Jun; 51(6):805-18. PubMed ID: 20663996
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
Himber J; Kirchhofer D; Riederer M; Tschopp TB; Steiner B; Roux SP
Thromb Haemost; 1997 Sep; 78(3):1142-9. PubMed ID: 9308768
[TBL] [Abstract][Full Text] [Related]
18. Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
Tomaru T; Nakamura F; Aoki N; Sakamoto Y; Omata M; Uchida Y
Heart Vessels; 1996; 11(3):133-44. PubMed ID: 8897062
[TBL] [Abstract][Full Text] [Related]
19. Ecarin Clotting Time: a predictive coagulation assay for the antithrombotic activity of argatroban in the rat.
Berry CN; Lunven C; Girardot C; Lechaire I; Girard D; Charles MC; Ferrari P; O'Brien DP
Thromb Haemost; 1998 Jan; 79(1):228-33. PubMed ID: 9459352
[TBL] [Abstract][Full Text] [Related]
20. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Mehta JL; Chen L; Nichols WW; Mattsson C; Gustafsson D; Saldeen TG
J Cardiovasc Pharmacol; 1998 Mar; 31(3):345-51. PubMed ID: 9514177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
